ImmunityBio Shares Rise on Positive Results From Lung Cancer Drug Trials

Dow Jones

Jan 14

By Amira McKee

Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients.

The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks.

The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells.

In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer.

ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added.

Write to Amira McKee at amira.mckee@wsj.com

(END) Dow Jones Newswires

January 13, 2026 16:09 ET (21:09 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2603630005"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603630005\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603630005?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-14 05:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603630005","market":"hk","top_or_hot":-1,"title":"ImmunityBio Shares Rise on Positive Results From Lung Cancer Drug Trials","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients. \n</p>\n<p>\n  The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks. \n</p>\n<p>\n  The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells. \n</p>\n<p>\n  In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer. \n</p>\n<p>\n  ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:09 ET (21:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmunityBio Shares Rise on Positive Results From Lung Cancer Drug Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmunityBio Shares Rise on Positive Results From Lung Cancer Drug Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-01-14 05:09</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n  By Amira McKee \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients. \n</p>\n<p>\n  The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks. \n</p>\n<p>\n  The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells. \n</p>\n<p>\n  In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer. \n</p>\n<p>\n  ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Amira McKee at amira.mckee@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  January 13, 2026 16:09 ET (21:09 GMT)\n</p>\n<p>\n  Copyright (c) 2026 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IBRX","symbol_name":"ImmunityBio, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2603630005","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603630005","pubTimestamp":1768338540,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients.The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks.The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells.In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer.ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IBRX":"ImmunityBio, Inc.","BK4139":"生物科技"},"translate_title":"ImmunityBio股价因肺癌药物试验取得积极结果而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IBRX":0.9},"content_text":"By Amira McKee \n\n\n \n\n\n  Shares of ImmunityBio rose to a three-month high after the company reported positive results from clinical trials of its Anktiva immunotherapy to treat lung cancer patients. \n\n\n  The stock closed the market session up 8.9% at $2.82 on Tuesday. Shares have risen 21% in the last 52 weeks. \n\n\n  The clinical stage immunotherapy company said Anktiva, in tandem with check point inhibitor therapy, produced statistically significant immune restoration in lung cancer patients. Anktiva is designed to restore the immune system of cancer patients by activating natural killer cells and T cells. \n\n\n  In two clinical trials across 151 patients with non-small cell lung cancers, those treated with Anktiva saw higher counts of cancer-fighting white blood cells and survived longer. \n\n\n  ImmunityBio said it was preparing the detailed results of the two studies for peer-review publication and future scientific presentations. A randomized Phase 3 confirmatory trial is continuing, it added. \n\n\n \n\n\n  Write to Amira McKee at amira.mckee@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 13, 2026 16:09 ET (21:09 GMT)\n\n\n  Copyright (c) 2026 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}